Shandong Boan Biotech says China CDE accepts IND filing for BA2201 bispecific antibody

PUBT · 3d ago
Shandong Boan Biotech says China CDE accepts IND filing for BA2201 bispecific antibody
  • China’s CDE accepted an IND application for Shandong Boan Biotechnology’s BA2201, a TL1A/IL-23 bispecific antibody.
  • Program targets inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.
  • Acceptance clears the way for China clinical trials; Boan expects BA2201 to be among the first TL1A/IL-23 bispecifics in-country.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12300535), on August 26, 2026, and is solely responsible for the information contained therein.